Phase 2 Study PTX-022 Sirolimus Gel 3.9% for Angiokeratomas
Summary
NCT07552077 is a Phase 2, baseline-controlled study evaluating the safety and efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the treatment of angiokeratomas. The study is registered with condition angiokeratomas and intervention PTX-022, with an anticipated study date of April 27, 2026. This is an informational clinical trial record posted to ClinicalTrials.gov, representing a study listing rather than a regulatory action or compliance requirement.
“The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07552077 is a Phase 2 clinical trial registration for PTX-022 (Sirolimus) Topical Gel 3.9% being studied for the treatment of angiokeratomas. The study is baseline-controlled and evaluates both safety and efficacy of the experimental topical gel formulation.
For affected parties, this study record provides transparency into ongoing clinical research for angiokeratomas treatment. Healthcare providers, researchers, and patients seeking investigational treatment options may reference this record for awareness of active Phase 2 trials. The record does not impose compliance obligations or regulatory requirements on any party.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Phase 2 NCT07552077 Kind: PHASE2 Apr 27, 2026
Abstract
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Conditions: Angiokeratomas
Interventions: PTX-022
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.